,,iv #aag? ,,congress #b;d ,session ,h4 ,,res4 #aejf ,,9 ,,! ,,h\se ,,( ,,repres5tatives ,decemb] #a1 #bjbb,ms4 ,williams ( ,georgia 7= h]self & ,ms4 ,lee ( ,cali=nia7 submitt$ ! foll[+ resolution2 :i* 0 ref]r$ to ! ,committee on ,en]gy & ,comm]ce ,,resolution ,express+ support = cont9u$ inve/m5t to complete ! developm5t ( an ,,hiv vacc9e4 ,:]eas ,,hiv affects ! entire globe & exi/s 9 a v>iety ( subtypes2 ,:]eas1 9 #bjai1 ! e/imat$ numb] ( new ,,hiv infections 9 adults & adolesc5ts 0 approximately #cd1hjj1 & ! ov]all rate ( new ,,hiv infections 0 #ab4f cases p] #ajj1jjj p 9 ! ,unit$ ,/ates2 ,:]eas1 at ! end ( #bjai1 ! e/imat$ ,,hiv preval5ce rate = p]sons #ac ye>s ( age & old] 9 ! ,unit$ ,/ates 0 #dca4j p] #ajj1jjj p2 ,:]eas1 z ( #bjai1 ,black ,am]icans h a rate ( ,,hiv infection t is #h4a times high] ?an t ( ,:ite ,am]icans2 ,:]eas1 9 #bjai1 !re 7 #f4j cases ( ,,hiv p] #ajj1jjj p t progress$ f ,,hiv to ,,aids 9 ! ,unit$ ,/ates2 ,:]eas1 at ! end ( #bjai1 ! ,,aids preval5ce rate among adults & adolesc5ts 9 ! ,unit$ ,/ates 0 e/imat$ at #aib4c p] #ajj1jjj p2 ,:]eas1 ea* ye>1 m ?an #ab1jjj p ) ,,aids die 9 ! ,unit$ ,/ates2 ,:]eas ! p diagnos$ ) ,,hiv 9 #bjah 9 ! ,unit$ ,/ates w pay a comb9$ e/imat$ lifetime total ( #ac1gjj1jjj1jjj 9 direct m$ical exp5ses2 ,:]eas x is e/imat$ t pati5ts on antiretroviral !rapy ) access to disc\nt$ m$ication h lifetime m$ical co/s av]ag+ #dbj1bhe1 :i* rises to an av]age ( #a1jgi1iii = pati5ts )\t su* access1 bas$ on an e/imat$ life expectancy ( #cg4ca ye>s aft] diagnosis2 ,:]eas1 9 fiscal ye> #bjbb alone1 ,unit$ ,/ates ,f$]al dome/ic discretion>y fund+ = ,,hiv_/,,aids programs total$ #g1dbe1hjj1jjj2 ,:]eas ! ,unit$ ,/ates has contribut$ a total ( #bc1agj1jjj1jjj s9ce #bjjb to ! ,global ,fund to ,fight ,,aids1 ,tub]culosis & ,mal>ia1 a multilat]al ef=t support$ by a numb] ( c\ntries & nongov]nm5tal organizations2 ,:]eas alt]natives = prev5t+ ,,hiv transmission1 =m]ly limit$ to ab/95ce1 education1 circumcision1 & condoms1 n[ include ,,hiv prev5tion m$ic9es su* z preexposure prophylaxis 7,pr,e,p7 & po/exposure prophylaxis 7,,pep72 ,:]eas #c ,,hiv vacc9es 7,,bg#eje ,,md#ci4c m,r,n,a1 ,,bg#eje ,,md#ci4c gp#aea m,r,n,a1 & ,,bg#eje ,,md#ci4c gp#aea ,,cd#d,,ko m,r,n,a7 are curr5tly 9 ,national ,in/itutes ( ,heal?-fund$ phase #a trials2 ,:]eas ,presid5t ,bid5 has pl$g$ to develop & implem5t a compreh5sive national ,,hiv_/,,aids /rategy t w include a focus on r$uc+ ,,hiv incid5ce2 & ,:]eas cont9u$ gov]nm5t inve/m5t t[>d a viable ,,hiv vacc9e has ! pot5tial to improve public heal? 9 ! ,unit$ ,/ates3 ,n[1 !re=e1 be x ,t ! ,h\se ( ,repres5tatives /rongly enc\rages dome/ic ef=ts 9 ! public & private sectors to inve/ 9 & complete ! developm5t ( a vacc9e = ,,hiv4